Brasada Capital Management LP Takes Position in Elanco Animal Health Incorporated $ELAN

Brasada Capital Management LP acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 30,010 shares of the company’s stock, valued at approximately $679,000.

A number of other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Elanco Animal Health by 1.6% during the third quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock valued at $978,536,000 after purchasing an additional 759,623 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Elanco Animal Health by 1.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock valued at $567,622,000 after purchasing an additional 373,869 shares during the period. UBS Group AG raised its stake in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after purchasing an additional 5,961,457 shares during the period. Geode Capital Management LLC raised its stake in shares of Elanco Animal Health by 7.3% during the fourth quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock valued at $213,343,000 after purchasing an additional 640,098 shares during the period. Finally, Fuller & Thaler Asset Management Inc. raised its stake in shares of Elanco Animal Health by 16.1% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 5,771,622 shares of the company’s stock valued at $130,612,000 after purchasing an additional 799,745 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Leerink Partners lifted their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. KeyCorp lifted their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Citigroup raised their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

Elanco Animal Health Stock Up 0.6%

ELAN stock opened at $24.19 on Friday. Elanco Animal Health Incorporated has a twelve month low of $13.15 and a twelve month high of $27.72. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $12.08 billion, a P/E ratio of -48.39, a PEG ratio of 1.58 and a beta of 1.69. The firm has a 50 day simple moving average of $22.90 and a 200-day simple moving average of $23.47.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter last year, the company earned $0.37 earnings per share. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Elanco Animal Health news, insider Rajeev A. Modi acquired 4,911 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.